BRAF inhibitor (vemurafenib) concurrent with radiation therapy for metastatic melanoma producing severe skin and oral cavity reactions

Pract Radiat Oncol. 2014 Sep-Oct;4(5):e213-e216. doi: 10.1016/j.prro.2013.10.007. Epub 2013 Dec 10.

Authors

Jonathan B Wallach¹, Petra Rietschel², Shalom Kalnicki¹, Jana L Fox³

Affiliations

¹ Department of Radiation Oncology, Montefiore Medical Center and the Albert Einstein College of Medicine, Bronx, New York.
² Department of Medical Oncology, Bayer Hospital, Wayne, New Jersey.
³ Department of Radiation Oncology, Montefiore Medical Center and the Albert Einstein College of Medicine, Bronx, New York. Electronic address: jfox@montefiore.org.

PMID: 25194107
DOI: 10.1016/j.prro.2013.10.007

No abstract available

Publication types

Case Reports

MeSH terms

Aged, 80 and over
Brain Neoplasms / complications*
Brain Neoplasms / secondary
Brain Neoplasms / therapy
Chemoradiotherapy / adverse effects*
Fatal Outcome
Female
Humans
Indoles / adverse effects*
Lymphatic Metastasis
Melanoma / complications*
Melanoma / pathology
Melanoma / therapy
Mouth Diseases / etiology*
Mouth Diseases / therapy
Neoplasm Invasiveness
Proto-Oncogene Proteins B-raf / antagonists & inhibitors
Skin Diseases / etiology*
Skin Diseases / therapy
Sulfonamides / adverse effects*
Vemurafenib

Substances

Indoles
Sulfonamides
Vemurafenib
BRAF protein, human
Proto-Oncogene Proteins B-raf